Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ALFACELL WILL FILE IND FOR ANTICANCER BIOLOGICAL PANNON,

Executive Summary

ALFACELL WILL FILE IND FOR ANTICANCER BIOLOGICAL PANNON, the company announced Aug. 12, after meeting with FDA's Center for Drugs and Biologics in a prefiling conference to discuss details of the proposed study. The filing will reportedly take place in eight to ten weeks, and the company is planning to conduct a multi-center trial in the U.S. The release noted that Alfacell's pre-filing conference with FDA was based on a clinical study conducted in the Domenican Republic, in which 27 terminal cancer patients were treated with Pannon. According to Dr. Angel S. Chan Aquino, former Domenican Minister of Health and director of the clinical trial, all patients "showed significant malignant cell destruction." It has also been reported that the drug did not produce any significant side effects.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel